Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10965814 | Vaccine | 2013 | 8 Pages |
Abstract
The HIV epidemic is greatest in Sub-Saharan Africa and India where HIV-1 subtype C is predominant. To control the spread of HIV in these parts of the world a preventive HIV-1 subtype C vaccine is urgently required. Here we report the immunogenicity of a candidate HIV-1 subtype C vaccine delivered by a recombinant measles vector carrying an insert encoding HIV-1 subtype C Gag, RT and Nef (MV1-F4), in MHC-typed non-human primates. HIV-1 specific cytokine secreting CD4+ and CD8+ T cell responses were detected in 15 out of 16 vaccinees. These HIV-specific T cell responses persisted in lymphoid tissues. Anti-HIV-1 antibody responses were detected in 15 out of 16 vaccinees and titres were boosted by a second immunisation carried out 84 days later. These findings support further exploration of the MV1-F4 vector as a candidate HIV-1 subtype C vaccine or as part of a wider vaccine strategy.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Richard Stebbings, Bo Li, Clarisse Lorin, Marguerite Koutsoukos, Michèle Février, Edward T. Mee, Mark Page, Neil Almond, Frédéric Tangy, Gérald Voss,